www.teijin.co.jp/news/2023/11/29/20231129_02.pdf

Latest saved version

帝人株式会社の希少内分泌疾患ホルモン治療薬に関する契約締結のお知らせ

This is the newest public snapshot for this URL and the best place to start reviewing the page.

Source URL

https://www.teijin.co.jp/news/2023/11/29/20231129_02.pdf

About this page

This document announces that Teijin Limited has signed an exclusive licensing agreement with Ascendis Pharma, A/S for three hormone therapies targeting rare endocrine disorders. The drugs involved are 'TransCon hGH', 'TransCon PTH', and 'TransCon CNP', and the agreement grants Teijin rights for research, development, manufacturing, and sales in Japan. Teijin will pay an upfront fee and milestone payments to Ascendis. The company aims to expedite the development of these therapies to deliver them to patients in Japan as soon as possible.